Tejara Capital Ltd Raises Holdings in QuidelOrtho Corporation $QDEL

Tejara Capital Ltd raised its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 97.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,327 shares of the company’s stock after purchasing an additional 102,700 shares during the period. QuidelOrtho comprises 1.4% of Tejara Capital Ltd’s investment portfolio, making the stock its 13th biggest position. Tejara Capital Ltd owned approximately 0.31% of QuidelOrtho worth $5,950,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in QDEL. Skylands Capital LLC grew its position in shares of QuidelOrtho by 28.5% during the fourth quarter. Skylands Capital LLC now owns 134,704 shares of the company’s stock worth $3,847,000 after buying an additional 29,879 shares in the last quarter. Camelot Portfolios LLC acquired a new stake in QuidelOrtho in the fourth quarter valued at approximately $29,000. Pictet Asset Management Holding SA raised its holdings in QuidelOrtho by 19.8% in the fourth quarter. Pictet Asset Management Holding SA now owns 12,413 shares of the company’s stock valued at $355,000 after acquiring an additional 2,054 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in QuidelOrtho by 7.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,404 shares of the company’s stock worth $583,000 after acquiring an additional 1,366 shares during the last quarter. Finally, Phocas Financial Corp. grew its holdings in QuidelOrtho by 45.7% during the 4th quarter. Phocas Financial Corp. now owns 170,018 shares of the company’s stock worth $4,856,000 after acquiring an additional 53,353 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

Analyst Upgrades and Downgrades

QDEL has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. Jefferies Financial Group downgraded shares of QuidelOrtho from a “buy” rating to a “hold” rating and lowered their target price for the stock from $35.00 to $12.50 in a research note on Thursday, May 7th. Wall Street Zen lowered QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. UBS Group reaffirmed a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a report on Thursday, May 7th. Finally, Zacks Research downgraded QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. Three research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, QuidelOrtho presently has a consensus rating of “Reduce” and an average target price of $14.88.

QuidelOrtho Stock Up 3.1%

QDEL opened at $11.39 on Friday. QuidelOrtho Corporation has a one year low of $9.92 and a one year high of $35.58. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The stock has a market capitalization of $776.68 million, a P/E ratio of -0.64 and a beta of 0.75. The business’s 50-day simple moving average is $14.98 and its 200-day simple moving average is $22.91.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The firm had revenue of $619.80 million during the quarter, compared to analyst estimates of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period last year, the company earned $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Analysts anticipate that QuidelOrtho Corporation will post 1.83 EPS for the current year.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.